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Abstract In search of a cell line in which the D3 dopamine
receptor is expressed endogenously, we found that the neuron-
derived human medulloblastoma cell line TE671 expresses the
human D3 (hD3) and D1 (hD1) receptor, but neither the D2 or
D4 receptors. Exposure of TE671 cells to the D3 agonist 7-OH-
DPAT (DPAT), or to the D1 agonist SKF-38393 (SKF)
increased the expression of hD3 or hD1 mRNA, respectively.
Moreover, whereas DPAT had no effect on hD1 mRNA levels,
stimulating the cells with SKF caused an increase in both hD1
and hD3 transcript levels. These results suggest (i) that following
ligand stimulation, hD3 and hD1 receptors are upregulated to
enhance their own receptor expression, and (ii) that upregulation
of hD1 receptor transcripts leads to a stimulation of the hD3
dopamine receptor transcripts.
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1. Introduction
Dopamine receptors have generally been divided into two
broad categories, referred to as D1 and D2 receptors. Both
belong to the family of receptors which are coupled to their
speci¢c e¡ector functions via guanine nucleotide regulatory
(G) proteins [1]. Both D1 and D2 receptors are present pre-
dominantly in the central nervous system (CNS) and exhibit
similar regional localizations. The D1 receptor family consists
of D1 and D5 [2,3] while thus far three D2-like receptors have
been cloned including the D2 [4], D3 [5], and D4 [6] subtypes.
The D3 dopamine receptor is thought to be associated with
behavioral aspects of dopaminergic function [7], and thus rep-
resents a therapeutic target in a number of neurological dis-
orders, notably Parkinson’s disease and schizophrenia [8]. The
D3 receptor is present at much lower levels in the brain than
the D2 subtype, and is expressed predominantly in limbic
areas including the olfactory tubercle, nucleus accumbens
and hypothalamus [5,9]. The only brain regions in which it
has been found to be expressed in the absence of the D2 and/
or D4 subtypes are the islands of Calleja [10,11]. Recent work
from our laboratory has demonstrated that mice lacking the
D3 dopamine receptor are hyperactive and exhibit reduced
levels of anxiety [12,13]. In addition, the D3 receptor is ex-
pressed in the dopaminergic neurons of the substantia nigra,
which, together with its high a⁄nity for the autoreceptor-
selective compounds AJ76 and UH232, supports the notion
that it may act as an autoreceptor [5].
One of the principal problems in studying the functional
properties of the D3 receptor is the di⁄culty of ¢nding high
a⁄nity D3-speci¢c ligands which do not bind to the D2 and
D4 subtypes. This, together with the relatively low levels of D3
receptor mRNA expression in the brain, and its colocalization
with the D2 and/or D4 receptor subtypes, has hampered stud-
ies of the functional properties of the D3 receptor. The avail-
ability of the cloned cDNA encoding the D3 receptor provides
a useful means of studying its activity in ectopic expression
systems, but has the drawback that the receptor is not in its
normal cellular environment and may therefore lack some of
the necessary elements of its signal transduction pathway. In
addition, in transfected cell systems the receptor’s expression
is not under the control of its own promoter elements, but is
under the control of the promoter present in the transfection
vector. In order to study the functional properties of the D3
receptor in a more native environment, we have searched for a
cell line in which this subtype is expressed endogenously. We
report here that the neuron-derived human medulloblastoma
cell line TE671 expresses the D3 and D1 receptor subtypes,
but neither the D2 nor D4 dopamine receptors. We also show
that stimulation of the D3 receptor leads to its own upregu-
lation, and stimulation of the D1 receptor leads to upregula-
tion of both D1 and D3 receptors, providing direct evidence of
cross-talk between these two dopamine receptors.
2. Materials and methods
2.1. Materials
Cell culture media were from Gibco Laboratories (Grand Island,
NY, USA). Oligonucleotide probes were synthesized by the labora-
tory of oligonucleotide synthesis at the Weizmann Institute of Science.
Dopamine, 7-OH-DPAT (7-hydroxy-N,N-di-n-propyl-2-aminotetra-
lin; DPAT), butaclamol, haloperidol, SKF-38393 (1-phenyl-2,3,4,5-
tetrahydro-(1H)-3-benzazepine-7,8-diol hydrochloride; SKF), and
SCH-23390 (7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahy-
dro-1H-3-benzazepine; SCH) were purchased from RBI (Natick,
MA, USA); U99194A maleate (5,6-dimethoxy-2-(di-n-propylami-
no)indan melate; U99) was a gift from Upjohn (Kalamazoo, MI,
USA).
2.2. Methods
2.2.1. Cell culture. TE671 cells were obtained from the ATCC and
grown in Dulbecco’s Modi¢ed Eagle’s Medium (DMEM) supple-
mented with 10% FCS (fetal calf serum), 1 mM glutamine, 30 Wg/ml
gentamicin sulfate, 100 U/ml penicillin, 100 Wg/ml streptomycin and
250 Wg/ml fungizone. Cells were maintained in a humidi¢ed incubator
(5% CO2) at 37‡C. Adherent cells were dislodged by treatment with
trypsin (0.25%) and were seeded at approximately 2U106 cells/10-cm
diameter dish, one day before the experiment. The cells were stimu-
lated with the drugs in DMEM containing 0.1% BSA for the time
periods indicated, while exposure to antagonists was carried out
10 min before agonist treatment.
2.2.2. Genomic library screening. An EMBL human genomic li-
brary (Clontech) was screened using a randomly primed cDNA frag-
ment encoding the human D3 receptor, or end-labeled oligonucleoti-
des based on the D3 receptor’s cDNA sequence [14]. DNA from
positive clones was isolated using Lambda maxi-prep columns (Quia-
gen), and was excised using the enzyme XhoI. DNA preparations were
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subjected to restriction digestion, Southern analysis, and hybridization
with appropriate oligonucleotide probes based on the D3 receptor
sequence, in order to allow identi¢cation and characterization of the
genomic fragments. Suitable fragments were excised and subcloned
into pBluescript (Stratagene) for sequence analysis. All molecular bio-
logical techniques were performed according to standard procedures
[15].
2.2.3. Northern analysis. Total RNA was prepared from cultured
cells using Tri-Reagent (MRC, OH, USA), and from human or mouse
tissues using the guanidium thiocyanate-caesium chloride method [16].
For Northern analysis, 25 Wg total RNA was denatured and was then
transferred onto and ¢xed to nylon Genescreen Plus membranes (Bos-
ton, MA, USA). Prehybridization, hybridization and washes were
performed according to the manufacturer’s instructions, prior to auto-
radiography.
2.2.4. RT-PCR. Total RNA from TE671 cells was reverse tran-
scribed and subjected to PCR, essentially as described previously [9].
For PCR, D3-speci¢c primers, based on the sequence of the human
D3 dopamine receptor [14] were used, containing XbaI adapters
(shown in small letters) (5P-ccgtctagATGGCATCTCTGAGTCA-
GCTG-3P and 5P-ccgtctagaCCTGGCAGCTAGAAATGG-3P). PCR
products were electrophoresed, and fragments were subcloned to the
vector pBluescript (Stratagene) by standard procedures [15].
For semiquantitative RT-PCR total RNA was extracted from
TE671 cells as described above. The sequences of the oligonucleotide
primers that were used for PCR ampli¢cation of fragments of the
hD1, hD2, hD3, hD4 and L-actin mRNA are shown in Table 1.
PCR ampli¢cation was performed as described previously [9] in a
DNA thermal cycler (Progene, Techne); 23 cycles were carried out
for L-actin, 27 cycles for hD3 and hD1, and 36 cycles for hD2 or hD4.
The amount of cDNA taken for PCR and the linear range of ampli-
¢cation for each primer pair were established in independent prelimi-
nary studies. Oligonucleotides speci¢c for the hD3 receptor (5P-
TGGGTGGTATACCTGGAGG-3P, hD1 receptor (5P-ACATTCGA-
CAGGCTTTCCATTACC-3P, or for L-actin (5P-TGCCACCAGA-
CAGCACTGTGTTGGC-3P) were labeled with [Q-32P]dATP using
T4 polynucleotide kinase (Boehringer), and were used in hybridiza-
tion. The membranes were hybridized and washed according to the
manufacturer’s recommendations and then exposed to a phosphor-
imager (BAS 1000, Fuji) for 2 h.
3. Results
3.1. Identi¢cation of endogenous D3 receptor expression in
TE671 cells
Total RNA was extracted from TE671 cells and subjected
to Northern analysis using a 450-bp EcoRI-SalI N-terminal
fragment of the murine D3 dopamine receptor [9]. A speci¢c
signal was obtained in TE671 cells at approximately 4 kb,
di¡erent in size from the 8.3-kb mRNA for the murine D3
receptor (Fig. 1, left). This 4-kb signal for the human D3
receptor mRNA was also observed using a probe derived
from the 3rd cytoplasmic loop of the human D3 receptor
and was detected in RNA from both TE671 cells and from
human neonatal brain tissue (data not shown), con¢rming
that the D3 receptor expressed in this cell line resembles the
human D3 receptor expressed in brain tissue. To determine
whether TE671 cells express the D2 subtype, the Northern
blot in Fig. 1, left, was deprobed, and was rehybridized using
a HindII-SacI fragment of the D2 dopamine receptor. No D2
receptor signal could be detected in the TE671 cells, whereas a
strong signal was seen at approximately 2.9 kb in the mouse
olfactory tubercle (Fig. 1, right), as expected for the D2 sub-
type [4].
To characterize further the D3 receptor expressed in TE671
cells, RT-PCR was performed on TE671 cell RNA, using
primers based on the N-terminal and C-terminal regions of
the human D3 dopamine receptor, previously isolated from
neonatal brain tissue [14]. Ethidium bromide staining revealed
a 1.2-kb PCR product, which hybridized with a human D3-
speci¢c oligonucleotide. This product was subcloned and se-
quenced, and found to represent the full length human D3
receptor, con¢rming that the D3 receptor present in the cell
line TE671 is identical to that in brain tissue1. The TE671-
derived clone contained only two silent changes (at positions
876 and 900) from the published human D3 gene [14] which
was isolated from human brain tissue. No speci¢c signals were
ampli¢ed by PCR using primers speci¢c for the D2, and D4
receptors, signifying that these dopamine receptor subtypes
are not expressed in the TE671 cell line (data not shown).
However, TE671 cells were found to contain D1 dopamine
receptor mRNA using RT-PCR with D1-speci¢c primers,
and sequencing of the ampli¢ed product showed it to be iden-
tical to the previously described human D1 receptor [2].
3.2. Comparison of the murine and human D3 receptor genes in
the third cytoplasmic domain
The nucleotide sequence of the PCR product of the 1.2-kb
full-length D3 receptor encodes a protein shorter than the
long isoform of the mouse D3 receptor (D3L) by 46 amino
acids, located in the receptor’s putative third cytoplasmic
loop. In addition, this 46 amino acid stretch overlaps with
the 21 amino acids lacking in the short isoform of the murine
D3 receptor (D3S) [9]. We have previously examined the in-
tron-exon organization of the murine D3 receptor and found
that the 5P and 3P borders of the 46 amino acid stretch co-
incide with intron 4 and the alternatively spliced intron 5,
respectively [17]. This led us to speculate whether there may
be other (longer) splice variants of the human D3 receptor.
Since this could only occur if an intron was present in this
region, we examined this section of the human D3 receptor
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Table 1
Primer sequences used for RT-PCR
Receptor Sequence (5P to 3P) Sense/nonsense Residues (nt) Size of PCR product (nt)
hD3 tct agATGGCATCTCTGAGTCAGCTG Sense 1^21 705
CCTGACACTGTTGCACTGAC Antisense 705^686
hD1 GGATTGCCACTCAAGCGGTC Sense 99^118 1254
CTCTATGGCATTATTCGTCGCAGG Antisense 1330^1353
L-Actin CCTTCAACACCCCAGCCATGTACG Sense Exon 4 501
TGCCACCAGACAGCACTGTGTTGGC Antisense Exon 5
hD2 ggaattcCCATGCTGTACAATACG Sense 775^798 994
gga aTTCCTGCTCACGGTTCG Antisense 785^1769
hD4 TGGCACGTCGCGCCAAGCTG Sense 769^788 540
CATCTCCTTGGTCCCTGAG Antisense 3P non-coding
1 GenBank accession number: U32499.
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gene. A human genomic library was screened using a 340-bp
NcoI-EcoRI C-terminal fragment of the D3 receptor, extend-
ing from the distal half of the third cytoplasmic loop to the C-
terminus. Examination of two genomic clones containing the
putative third cytoplasmic loop revealed the presence of an
intron exactly at the position where the human and murine D3
receptors diverge, and restriction analysis and Southern blot-
ting demonstrated this intron to be over 7 kb in size (Fig. 2).
Thus, in the third cytoplasmic domain of the D3 receptor, the
human D3 receptor gene appears to have one 7-kb intron,
whereas the murine homologue contains two introns, and
has exonic sequence encoding an extra 25 (D3S) or 46 (D3L)
amino acids.
3.3. Upregulation of transcripts of hD3 and hD1 dopamine
receptors
TE671 cells provide an easy and useful means of investigat-
ing the in£uence of dopaminergic agonists on D3 receptor
levels, as they endogenously express D3 receptors in the ab-
sence of D2 and D4 dopamine subtypes. We therefore treated
TE671 cells with dopamine (100 WM) in the presence or ab-
sence of the D2 antagonist butaclamol (10 WM), for increasing
periods of time, and examined the e¡ect on the level of the D3
receptor mRNA. Exposures to dopamine of 20^30 min pro-
duced elevated hD3 mRNA levels (Fig. 3a,b), while the
mRNA levels of L-actin did not change (data not shown).
This rise in hD3 mRNA levels started to drop with longer
exposures to dopamine, showing this to be a short-lived e¡ect.
The increase in hD3 mRNA was sensitive to the dopaminergic
antagonist butaclamol con¢rming the receptor speci¢city of
this e¡ect (Fig. 3a). The speci¢city of the signal was also
con¢rmed by RT-PCR. Cells were treated for 30 min, and
RT-PCR was performed on cellular RNA using speci¢c prim-
ers (Table 1) to amplify a 700-bp fragment from the 5P end
of the hD3 receptor. The mRNA expression of the hD3 re-
ceptor was increased following dopamine treatment and this
was attenuated by the antagonist haloperidol (Fig. 3b). This
increase in hD3 receptor mRNA levels was both rapid and
short-lived.
As mentioned earlier, RT-PCR on TE671 cell RNA with
receptor speci¢c primers demonstrated that while D2 and D4
receptors are not present in these cells, the hD1 subtype is
expressed. We therefore used Northern blot analysis to exam-
ine the e¡ect of dopaminergic agonists on hD1 receptor
mRNA levels. Exposure of the cells to 100 WM dopamine
caused a signi¢cant increase in mRNA levels of the hD1 re-
ceptor after 20 min; this e¡ect persisted up to 40 min stim-
ulation, and was abolished by the presence of butaclamol
(Fig. 3c). This was con¢rmed by RT-PCR using speci¢c
hD1 receptor primers. Dopamine signi¢cantly increased the
level of the hD1 receptor mRNA, and addition of the antag-
onist haloperidol abolished the e¡ect (Fig. 3d).
3.4. Cross-talk between hD1 and hD3 receptors in TE671
The endogenous expression of both D1 and D3 receptors in
the same cell line allowed us to analyze whether cross-talk
occurs between these two receptor systems. To di¡erentiate
between these two systems, D1- and D3-speci¢c ligands were
used to treat the cells. TE671 cells incubated with the D3-
speci¢c agonist DPAT showed a rapid increase in hD3
mRNA levels, which was abolished in the presence of the
D3-speci¢c antagonist U99 (Fig. 4). The D3 agonist DPAT
had no e¡ect on hD1 mRNA levels. However, stimulating
the cells with the D1 agonist SKF caused an increase in
both hD1 and hD3 transcript levels (Fig. 4). The speci¢c D3
antagonist U99, given together with SKF, had no signi¢cant
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Fig. 2. The intron at the third cytoplasmic loop of the human D3 receptor gene. a: Schematic representation of the position of the newly iden-
ti¢ed intron in the human D3 receptors. b: DNA sequence of the donor and acceptor sites of the newly identi¢ed intron in the human D3 re-
ceptor.
Fig. 1. Identi¢cation of D3 dopamine receptor mRNAs in TE671
cells. Northern analysis of mRNA from TE671 cells (1), mouse ol-
factory tubercle (2) and CHO cells (3), using cDNA probes encod-
ing the D3 receptor (left) and D2 receptor (right).
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e¡ect on the level of hD3 and hD1 mRNAs. However, the D1
antagonist SCH abolished the e¡ect of SKF on hD1 and
markedly decreased its e¡ect on hD3 receptor mRNA level
(Fig. 4).
4. Discussion
In this paper we report the identi¢cation of a cell line
(TE671) which endogenously expresses both the D3 and D1
dopamine receptors in the absence of other dopamine receptor
subtypes, and demonstrate that this cell line presents a useful
and convenient system for examining speci¢c dopamine recep-
tor functions. The TE671 cell line is derived from neuronal
origin and has been widely used as a model of human medul-
loblastoma, having similar properties to cells originated from
the CNS [18]. It thus represents an excellent tool for studying
regulation of D3 receptor expression and activity.
The cloning and sequencing of the D3 receptor from TE671
cells con¢rmed that this receptor is identical to that expressed
in human brain, and led us to compare it with the murine D3
receptor. We have previously characterized the structural or-
ganization of the murine D3 receptor gene [17] and showed it
to contain two introns in the region encoding the putative
third cytoplasmic loop, one of which contains a variable splice
site which gives rise to the murine D3S receptor isoforms [9].
Partial analysis of the human D3 receptor gene was performed
by Giros et al. [14] who identi¢ed introns corresponding to
introns 1 and 6 in the murine D3 receptor gene. The present
report presents the ¢rst direct evidence of the intron organ-
ization in the 3rd cytoplasmic loop of the hD3 receptor gene,
and shows that the 7-kb intron present is located at a corre-
sponding position to introns 4 and 5 in the murine D3 recep-
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Fig. 4. Cross-talk between hD1 and hD3 receptors in TE671 cells.
PCR ampli¢cation of RNA-derived cDNA of TE671 cells stimu-
lated with either the D3 agonist DPAT (10 WM) or D1 agonist SKF
(10 WM), alone or in combination with the D3 antagonist U99
(1 WM) or the D1 antagonist SCH (1 WM). Southern blots were hy-
bridized with hD1 or hD3 speci¢c probes (see Section 2 for details).
Fig. 3. Up-regulation of hD3 and hD1 dopamine receptor transcripts in TE671. Northern blot analysis of mRNA extracted from TE671 cells
stimulated with dopamine (100 WM), for the indicated times, in the absence or presence of butaclamol (buta; 10 WM), and hybridized with a
D3 (a) or a D1 (c) speci¢c probe. Ethidium bromide staining of RT-PCR products using D3 (b) or D1 (d) primers on TE671 cells stimulated
with dopamine (DA; 100 WM) for 30 min, in the absence or presence of haloperidol (H; 10 WM). W is a water control.
B. Levavi-Sivan et al./FEBS Letters 439 (1998) 138^142 141
tor gene. In addition, the coincidence of the intron boundaries
with the location of the extra 46 amino acids in the murine
and rat receptors gives rise to the suggestion that other, longer
forms of the human D3 receptor may exist, analogous to the
D3S or D3L receptors present in the mouse.
Conceivably, there are at least two mechanisms by which
the mRNA levels of the hD1 or hD3 receptors could be ele-
vated in the TE671 cells. First, receptor activation could lead
to an increase in the stability of the receptor mRNA. If so,
this mRNA should contain sequence elements that interact
with cellular factors to regulate its stability [19]. A second
possibility is that TE671 cells contain regulatory elements
that modulate the transcriptional rate of the dopamine recep-
tors. Presumably, these could be enhancer or silent elements
that interact with speci¢c transcription factors and would be
either activated or inhibited, respectively, by dopamine recep-
tor activation. It should be emphasized that since the TE671
cells express the dopamine receptors endogenously, they con-
tain all the 3P and 5P untranslated regions that may be in-
volved in the transcription and/or stability of the dopamine
receptor mRNA.
Perhaps most interesting is the coexpression of D3 and D1
receptors in TE671 cells, and the ¢nding that cross-talk occurs
between these two receptor systems. Coexpression of D3 and
D1 receptors within the same neurons has been reported in
both the shell and core regions of the nucleus accumbens [20],
in neostriatal medium spiny neurons [21], and in striatonigral
neurons [22]. Moreover, both D1 and D3 receptors are present
in granule cells of the islands of Calleja, where the highest D3
receptor density in brain is found [10,11]. Obviously, this co-
localization raises the question of interaction between these
receptor systems. In TE671 cells, activation of either hD3 or
hD1 receptors by dopamine results in activation of signal
transduction cascades that are speci¢c to each receptor, lead-
ing to the increase in mRNA. We have shown that stimulation
of the hD1 receptor by SKF activates a signal transduction
cascade that leads to upregulation of both the hD1 and hD3
transcripts, while hD3 receptor activation leads to its own up-
regulation but has no e¡ect on hD1 mRNA levels. In the
brain, however, the endogenous ligand dopamine will presum-
ably not distinguish between receptor subtypes, and will acti-
vate both receptor cascades, unless some system operates to
sequester or down-regulate one or other of these signaling
pathways. Thus dopamine stimulation may lead to upregula-
tion of both hD1 and hD3 receptors in cells where they are
coexpressed. It seems paradoxical that D1 stimulation should
lead to up-regulation of D3 receptors, since these are classi-
cally thought to have opposing e¡ects, particularly with re-
spect to adenylate cyclase stimulation. However, recent data
from our laboratory [23] show that the D3 receptor may also
activate adenylate cyclase; consequently it may act in concert
with the D1 receptor to amplify a signal via cAMP produc-
tion, while also activating or inhibiting other e¡ector systems
which di¡er from D1 modulated pathways. It will be interest-
ing to determine how receptor activation leads to changes in
mRNA levels, and the TE671 cell line should present an ex-
cellent system for dissecting the downstream signaling compo-
nents of the D1 and D3 receptors, and for studying how these
two dopaminergic systems ‘talk’ to one another.
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